Niraparib (NCT04641247)

Name: Niraparib trial for Ovarian Neoplasms (NCT04641247)
Uploaded: 2026-10-31T22:55:09.848Z
Duration: 1 min 25 s
Description: Niraparib trial for Ovarian Neoplasms (NCT04641247). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04641247.

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study: a one-minute explainerNCT046412471 min

Niraparib trial for Ovarian Neoplasms (NCT04641247). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults already receiving niraparib in an eligible GSK or TESARO study, whose investigator judges continued treatment beneficial. It is an extension study, not general enrollment for new patients.

The idea: niraparib blocks PARP-mediated DNA repair. Participants continue oral treatment daily in ninety-day cycles, starting at their previous study dose. Researchers track long-term safety through blood tests, examinations, vital signs, and performance status. Permanent prior discontinuation excludes entry; unresolved treatment-interrupting toxicity must first resolve.

This phase 2 study plans 37 patients. GlaxoSmithKline sponsors it; nine US sites recruit.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.